Abstract: The invention provides lipid bodies isolated from yeast, compositions comprising the lipid bodies, products made from the lipid bodies, methods of making the lipid bodies, and methods of using the lipid bodies. The lipid bodies of the invention have an exceptionally large size and high internal neutral lipid content, providing a number of advantages for a variety of practical applications.

Abstract: The present disclosure relates to compositions and methods for restoring enamel, e.g., on tooth surfaces.

Abstract: A vegan anhydrous semi-solid composition may be provided, that includes at least 30% by weight of an organic solvent, a rheology modifier system, 5-15% by weight of waxes, and a particulate. The rheology modify system includes disteardimonium hectorite and silica silylate, where there is a ratio R1 of a percent by weight of disteardimonium hectorite to silica silylate that is 2.1?R1?6. The waxes include a hard wax and a soft wax. The particulate includes a pigment, a pearlescent agent, a filler, or a combination thereof.

Abstract: A disinfectant wipe is provided including a substrate that is substantially free of polyamides, and an acid anionic disinfectant is adsorbed to the substrate such that the disinfectant readily releases from the substrate to allow at least 65% delivery of the disinfectant when wiped on a surface. The substrate may be a woven, nonwoven, knit fabric, a foam, sponge or film composition and may be formed from polyester, polypropylene, nylon, cotton, rayon, acrylic, or combinations thereof. The acid anionic disinfectant has a pH below 7, below 5, below 3 and below 2. The substrate used to prepare the disinfectant wipe is not pretreated with the disinfectant or a release composition before applying the disinfectant. That is, the disinfectant is not applied and re-applied to ensure release onto a surface. In an embodiment of the invention acid anionic disinfectant is an antimicrobial agent.

Abstract: L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).

Abstract: The present invention relates to a composition comprising: (a) at least one pigment; (b) at least one first copolymer of at least two monomers selected from (meth)acrylic acid, esters thereof, and salts thereof; (c) at least one second copolymer of styrene or ?-methylstyrene and of at least one monomer selected from (meth)acrylic acid, esters thereof, and salts thereof, wherein the weight ratio of the amount of the (c) second copolymer(s)/the amount of the (a) pigment(s) is 1.0 or more, preferably 1.5 or more, and more preferably 2.0 or more, and the composition comprises at least one non-ionic surfactant in an amount of 0.5% by weight or less, preferably 0.3% by weight or less, and more preferably 0.1% by weight or less, relative to the total weight of the composition, or the composition comprises no non-ionic surfactant.

Abstract: Dissolvable unit dose film constructs are made by providing a muco-adhesive composition including a muco-adhesive polymer matrix in which the muco-adhesive polymer matrix has a water-soluble polymer, water-dispersible polymer, water-swellable polymer, or combinations thereof and a liquid carrier. The method further includes drying the muco-adhesive composition to remove at least a portion of the liquid carrier, forming a muco-adhesive film substrate, forming a composition for an active layer, the composition including a polymer matrix in which the polymer matrix for the active layer composition includes a water-soluble polymer, water-dispersible polymer, water-swellable polymer, or combinations thereof, an active ingredient and a liquid carrier.

Abstract: The invention relates to a method for producing an antimicrobially effective composite material (10), in which at least one molybdenum and/or tungsten containing inorganic compound is bound to at least one further material. Furthermore, the invention relates to an antimicrobially effective composite material (10), which includes at least one molybdenum and/or tungsten containing compound, which is bound to at least one further material.

Abstract: An oral care composition containing a gel phase, an abrasive, and a fluoride source. The gel network phase contains a fatty amphiphile and phase separation is not visually perceptible in the oral care composition.

Abstract: A composition includes diamine oxidase for use in prevention or treatment of symptoms and disorders caused by fibromyalgia or chronic fatigue syndrome.

Abstract: An aqueous eyebrow cosmetic includes a clay mineral, a film-forming polymer emulsion, and water, in which the content of the clay material is 5 to 20% by mass based on the total amount of the aqueous eyebrow cosmetic, the film-forming polymer emulsion includes a polymer having a glass transition temperature of ?20° C. or higher, and the content of the water is 30% by mass or greater based on the total amount of the aqueous eyebrow cosmetic.

Abstract: The present invention relates to functional foods comprising DAO and their use for the prevention or treatment of diseases or pathological conditions associated with high levels of histamine in blood, in particular for the prevention or treatment of migraine, chronic fatigue, fibromyalgia, spondylitis and pain caused by muscle contractures.

Abstract: There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form includes at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit including the same are also provided.

Abstract: A topical copper ion treatment in basic form composes a copper ion-containing solution composed of a biocompatible solution containing copper ions obtained by leaching of the copper ions from copper metal into the solution. The copper ion-containing solution can be combined with various carriers to form various forms of the copper ion treatment including creams, gels, lotions, foams, pastes, tampons, solutions, suppositories, body wipes, wound dressings, skin patches, and suture material. A method of making the copper ion-containing solution involves placing solid copper metal in a quantity of a biocompatible solution and maintaining the solution at a specified temperature for a predetermined period of time during which copper ions each from the copper metal into the solution, and thereafter separating the solution from the solid copper metal.

Abstract: A topical composition that destroys an external hyperplastic tissue, while preserving a basic architecture of the external hyperplastic tissue rather than dissolution of hydrolysis of protein peptide bonds of the external hyperplastic tissue, thereby providing a timely regeneration of healthy skin tissue after the external hyperplastic tissue has been treated with the topical composition, and thereby contributing to less damage to surrounding healthy skin tissue, as a result of, destructive potential of the topical composition being effectively neutralized and penetration of the topical composition into the surrounding healthy tissue being effectively blocked. The topical composition includes a caustic portion and a detoxifying and cleansing portion. The caustic portion has a caustic effect on the external hyperplastic tissue.

Abstract: An organic counteranion co-assembly strategy is employed to prepare a hybrid molecular framework. The hybrid molecular framework comprises an ordered arrangement of cyclodextrin (CD), metal cations, and organic anions.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: The disclosure relates to thermal control of compositions for altering the color of hair, in particular to hair bleaching compositions comprising thermal control agents, hair color-altering compositions comprising the hair bleaching compositions and/or thermal control agents, methods for preparing and using the hair color-altering compositions, and kits comprising the hair bleaching compositions and/or thermal control agents.

Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

Abstract: Techniques regarding the transportation of molecular cargo across the BBB are provided. For example, one or more embodiments described herein can comprise a chemical compound to facilitate molecular encapsulation of the molecular cargo. The chemical compound can comprise a diblock copolymer having a molecular backbone comprising a polycarbonate structure and a polyethylene glycol structure. Also, the polycarbonate structure can be functionalized with boronic acid.